search
Back to results

Rational Approach to a Unilateral Pleural Effusion2 (REPEAT)

Primary Purpose

Lung Neoplasms

Status
Terminated
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Contrast-enhanced CT
PET-CT
Sponsored by
Simon Reuter
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Lung Neoplasms focused on measuring Thoracoscopy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with recurrent pleural effusion of unknown origin after a first pleural tap according to BTS guidelines.
  2. Indication for thoracoscopy according to BTS guidelines.
  3. Patients accept further investigation according to Danish and BTS guidelines.
  4. Have received oral and written consent and agreed.
  5. At the time of inclusion, above 18 years of age.

Exclusion Criteria:

  1. Female patients: pregnancy or breastfeeding.
  2. Lack of language comprehension.
  3. Legally incompetent patients.
  4. Life expectancy less than 3 month.
  5. Contraindications to pleural tissue sampling.

Sites / Locations

  • Naestved Sygehus

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

CE-CT scanning

PET-CT scanning

Arm Description

Contrast-enhanced CT scan of the thorax and abdomen.

Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.

Outcomes

Primary Outcome Measures

Number of diagnostic thoracoscopies (either MT or VATS)

Secondary Outcome Measures

Number of derived investigations (i.e. gastroscopy, coloscopy)
Number of patients diagnosed with cancer (cancer = an unequivocal diagnosis of neoplastic disease; no cancer = clinically benign cause, and improved imaging at 6 month control)
Patient satisfaction and patient perceived discomfort
Using QLQC 30
Total costs calculated as costs patient-related, procedure-related, and overall
Total procedures before cancer-diagnosis (cancer = yes/no)
Patient satisfaction and patient perceived discomfort
EuroQol Q-5D a standardised instrument for use as a measure of health outcome

Full Information

First Posted
June 17, 2015
Last Updated
December 15, 2020
Sponsor
Simon Reuter
search

1. Study Identification

Unique Protocol Identification Number
NCT02834455
Brief Title
Rational Approach to a Unilateral Pleural Effusion2
Acronym
REPEAT
Official Title
Rational Approach to Unilateral Pleural Effusion in Patients Suspected of Malignancy. Efficacy, Pain, Quality of Life, and Economy
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Terminated
Why Stopped
Patient inclusion cannot be reached within timelimits
Study Start Date
May 2015 (Actual)
Primary Completion Date
December 15, 2020 (Actual)
Study Completion Date
December 15, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Simon Reuter

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Recurrent unilateral, non-infectious pleural exudate is suspicious for primary or secondary pleural malignancy. Both conditions are associated with 5-year survival of 10%. Work-up is difficult, as the pleural surface is large and <33% of pleural malignancies shed malignant cells to the pleural fluid. Even so, additional tissue biopsies are needed for establishing mutation status for targeted therapies. Optimal imaging to guide tissue sampling is pivotal. PET-CT has higher sensitivity than conventional CT for detecting malignant lesions >10mm. However, no randomised trial has investigated differences in diagnostic accuracy, time-to-diagnosis, or economics. Falsely PET-positive lesions in e.g. colon however, lead to more derived tests than do CT alone. Gold standard for pleural tissue sampling is the surgical (VATS) thoracoscopy, allowing direct visual guiding of tissue sampling from all pleural surfaces. Yet, globally the medical (pleuroscopy) thoracoscopy is more widely used: cheaper, outpatient procedure, but allows only sampling from the parietal pleura. To date, no randomised studies have compared medical and surgical thoracoscopy concerning diagnostic hit rates, adverse events, or economics. The investigators will perform two randomized studies to investigate whether PET/CT is comparable to CT alone VATS is comparable to pleuroscopy concerning hit rate, total investigations performed, time-to-diagnosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Neoplasms
Keywords
Thoracoscopy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CE-CT scanning
Arm Type
Active Comparator
Arm Description
Contrast-enhanced CT scan of the thorax and abdomen.
Arm Title
PET-CT scanning
Arm Type
Active Comparator
Arm Description
Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
Intervention Type
Device
Intervention Name(s)
Contrast-enhanced CT
Intervention Description
50% of patients with unilateral pleural effusion will have performed a CE-CT
Intervention Type
Device
Intervention Name(s)
PET-CT
Intervention Description
50% of patients with unilateral pleural effusion will have performed a PET-CT
Primary Outcome Measure Information:
Title
Number of diagnostic thoracoscopies (either MT or VATS)
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Number of derived investigations (i.e. gastroscopy, coloscopy)
Time Frame
2 years
Title
Number of patients diagnosed with cancer (cancer = an unequivocal diagnosis of neoplastic disease; no cancer = clinically benign cause, and improved imaging at 6 month control)
Time Frame
2 years
Title
Patient satisfaction and patient perceived discomfort
Description
Using QLQC 30
Time Frame
2 years
Title
Total costs calculated as costs patient-related, procedure-related, and overall
Time Frame
2 years
Title
Total procedures before cancer-diagnosis (cancer = yes/no)
Time Frame
2 years
Title
Patient satisfaction and patient perceived discomfort
Description
EuroQol Q-5D a standardised instrument for use as a measure of health outcome
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with recurrent pleural effusion of unknown origin after a first pleural tap according to BTS guidelines. Indication for thoracoscopy according to BTS guidelines. Patients accept further investigation according to Danish and BTS guidelines. Have received oral and written consent and agreed. At the time of inclusion, above 18 years of age. Exclusion Criteria: Female patients: pregnancy or breastfeeding. Lack of language comprehension. Legally incompetent patients. Life expectancy less than 3 month. Contraindications to pleural tissue sampling.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Uffe Boedtger, MD, PhD
Organizational Affiliation
ubt@regionsjaelland.dk
Official's Role
Study Director
Facility Information:
Facility Name
Naestved Sygehus
City
Naestved
ZIP/Postal Code
4700
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

Rational Approach to a Unilateral Pleural Effusion2

We'll reach out to this number within 24 hrs